However, the issue was that the polymeric molecule would degrade quickly. In this research phase, scientists developed the ability for mRNA – a nucleic acid playing essential roles in coding, decoding, regulation, and expression of genes – to be taken up by the body. By the 1970s, research materialized regarding the process of how mRNA could be delivered into cells. However, as Johns Hopkins Bloomberg School of Public Health noted, mRNA vaccines actually feature a long history, being first discovered in the early 1960s. In particular, patient forward-looking investors may want to consider the following biotech stocks:ĭuring the initial development phase of mRNA vaccines for the SARS-CoV-2 virus, public hesitancy arose due to the “newness” factor of the innovative approach. Indeed, advanced biotechnology firms may be able to leverage this innovation to spark additional therapeutics. Though the disruptions it imposed may reverberate for years to come, it also sparked a major silver lining: the development and distribution of messenger-RNA-based vaccines. An experience that few want to relive is the COVID-19 crisis.
0 kommentar(er)
